{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:22:10Z","timestamp":1787631730966,"version":"build-2736575974"},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,3,31]],"date-time":"2019-03-31T00:00:00Z","timestamp":1553990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Data regarding the cardiac toxicity of cabozantinib lacks. The aim of our study was to assess the risk of cabozantinib\u2010related cardiotoxicity in mRCC patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a multicentre prospective study on mRCC patients treated with cabozantinib between October 2016 and November 2017. Transthoracic echocardiogram and plasma biomarkers assay were assessed at baseline, 3 and 6\u00a0months after cabozantinib initiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study population included 22 mRCC patients. At baseline, 9.1% had a reduced left ventricular ejection fraction (LVEF), but none had a left ventricular systolic dysfunction. Patients with baseline reduced LVEF did not show further significant LVEF modification after 3\u00a0months. After 6\u00a0months, only 1 had an LVEF decline &gt;10% compared to baseline, resulting in LV systolic dysfunction. At baseline, 64.7% and 27.3% of patients had elevated precursor brain natriuretic peptide (proBNP) and high\u2010sensitivity troponin I (hsTnI), respectively. Among patients with basal normal proBNP and hsTnI, none had elevated values at 3 and 6\u00a0months. No correlation was found between basal elevated proBNP and basal reduced LVEF (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.29), and between elevated proBNP and reduced LVEF after 6\u00a0months (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.37). Similarly, we found no correlations between elevated hsTnI and reduced LVEF or elevated proBNP at baseline (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.47; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.38), at 3 (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.059; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.45) and after 6\u00a0months (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.72; <jats:italic>P<\/jats:italic>\u00a0=\u00a01.0).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This prospective study revealed a modest risk of developing left ventricular systolic dysfunction related to cabozantinib. A lack of correlation between elevated cardiac biomarkers and reduced LVEF at different time\u2010points was detected. Assessments of the cardiac function should be reserved at the occurrence of clinical symptoms.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13895","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T05:58:55Z","timestamp":1549864735000},"page":"1283-1289","source":"Crossref","is-referenced-by-count":26,"title":["Cabozantinib\u2010related cardiotoxicity: a prospective analysis in a <i>real\u2010world<\/i> cohort of metastatic renal cell carcinoma patients"],"prefix":"10.1111","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1750-2117","authenticated-orcid":false,"given":"Roberto","family":"Iacovelli","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Azienda Ospedaliera Universitaria Integrata (AOUI)  Verona Italy"},{"name":"Oncologia Medica Fondazione Policlinico Universitario Agostino Gemelli IRCCS  Roma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ciccarese","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Azienda Ospedaliera Universitaria Integrata (AOUI)  Verona Italy"},{"name":"Oncologia Medica Fondazione Policlinico Universitario Agostino Gemelli IRCCS  Roma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology IRCCS Azienda Ospedaliera Universitaria San Martino\u2010Istituto Nazionale per la Ricerca sul Cancro  Genova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Sant'Orsola\u2010Malpighi Hospital  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bimbatti","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Azienda Ospedaliera Universitaria Integrata (AOUI)  Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mosillo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Azienda Ospedaliera Universitaria Integrata (AOUI)  Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Elena","family":"Rebuzzi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology IRCCS Azienda Ospedaliera Universitaria San Martino\u2010Istituto Nazionale per la Ricerca sul Cancro  Genova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Nunno","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Sant'Orsola\u2010Malpighi Hospital  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Grassi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology IRCCS Azienda Ospedaliera Universitaria San Martino\u2010Istituto Nazionale per la Ricerca sul Cancro  Genova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Fantinel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Azienda Ospedaliera Universitaria Integrata (AOUI)  Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Sant'Orsola\u2010Malpighi Hospital  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Azienda Ospedaliera Universitaria Integrata (AOUI)  Verona Italy"},{"name":"Oncologia Medica Fondazione Policlinico Universitario Agostino Gemelli IRCCS  Roma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,31]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw328"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30107-3"},{"issue":"5","key":"e_1_2_8_4_1","first-page":"v605","article-title":"Progression\u2010free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)","volume":"28","author":"Choueiri TK","year":"2017","journal-title":"Ann Oncol"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.6506"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61865-0"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.6331"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.4309"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2869"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2106"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000215207.54689.31"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2014.10.003"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.1611"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0215"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13876"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13877"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp025"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23460"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2016.1190269"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0335"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.3953"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2012.09.001"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13895","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13895","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.13895","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T07:11:52Z","timestamp":1694329912000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,31]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/bcp.13895"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13895","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,31]]}}}